Rhumbline Advisers Hutchmed (China) LTD Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Rhumbline Advisers holds 3,028 shares of HCM stock, worth $49,628. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,028
Previous 3,300
8.24%
Holding current value
$49,628
Previous $49,000
8.16%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding HCM
# of Institutions
62Shares Held
6.07MCall Options Held
0Put Options Held
0-
Schroder Investment Management Group London, X02.58MShares$42.3 Million0.03% of portfolio
-
Allianz Asset Management Gmb H Munich, 2M925KShares$15.2 Million0.02% of portfolio
-
State Street Corp Boston, MA329KShares$5.39 Million0.0% of portfolio
-
Aia Group LTD Hong Kong, K3315KShares$5.17 Million0.11% of portfolio
-
Goldman Sachs Group Inc New York, NY289KShares$4.74 Million0.0% of portfolio
About HUTCHMED (China) Ltd
- Ticker HCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 172,955,008
- Market Cap $2.83B
- Description
- HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...